This study will investigate whether the addition of Quercetin or Alpha-Lipoic Acid (ALA) to standard metformin therapy can improve symptoms, hormone levels, metabolic health, and quality of life in women with polycystic ovary syndrome (PCOS). Over 3 months, participants will be randomly assigned to one of three groups: metformin alone, metformin plus Quercetin, or metformin plus ALA. Researchers will measure changes in hormones, blood sugar, cholesterol, and antioxidant markers, as well as quality of life and medication adherence. Physical measurements and side effects will also be recorded to assess safety and overall benefit.
• Newly diagnosed patients should be at reproductive aged from 18-40 years.
Patients diagnosed with presence of micro polycystic ovaries at ultrasound.
Oligomenorrhea with inter-menstrual intervals longer than 35 days.
Clinical or biochemical signs of hyperandrogenism (acne, hirsutism).
• Presence of enzymatic adrenal deficiency and/or other endocrine disease, including diabetes.
Other comorbidities (such as hypertension, cardiovascular disease, or hormonal dysfunction).
Women who used oral contraceptives, hormonal therapy, or anti-lipidemic drugs.
Pregnant women.